Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty

Objective. GnRH analogues (GnRHa) are used in the treatment of central precocious puberty (CPP). The purpose of this study was to evaluate the efficacy of treatment with a GnRHa (leuprolide acetate) in patients with CPP. Subjects and Methods. A total of 62 female child patients who had been diagnose...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Endocrinology 2015-01, Vol.2015 (2015), p.404-410-045
Main Authors: Onder, Asan, Bas, Veysel N, Aycan, Zehra, Cetinkaya, Semra, Kendirci, H. Nur Peltek, Agladioglu, Sebahat Yilmaz
Format: Article
Language:English
Subjects:
Age
Clinical Study
Complications and side effects
Dosage and administration
Endocrinology
Gonadotropin releasing hormone
Laboratories
Leuprolide
Physical growth
Physiological aspects
Precocious puberty
Puberty
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. GnRH analogues (GnRHa) are used in the treatment of central precocious puberty (CPP). The purpose of this study was to evaluate the efficacy of treatment with a GnRHa (leuprolide acetate) in patients with CPP. Subjects and Methods. A total of 62 female child patients who had been diagnosed with CPP, rapidly progressive precocious puberty (RP-PP), or advanced puberty (AP) and started on GnRHa treatment (leuprolide acetate, Lucrin depot, 3.75 mg once every 28 days) were included in the study. The efficacy of treatment was evaluated with anthropometric data obtained, progression of pubertal symptoms observed, as well as GnRHa tests, and, when necessary, intravenous GnRH tests carried out in physical examinations that were performed once every 3 months. Results. In the current study, treatment of early/advanced puberty at a dose of 3.75 mg once every 28 days resulted in the suppression of the HHG axis in 85.5% of the patients. Conclusion. The findings of this study revealed that a high starting dose of leuprolide acetate may not be necessary in every patient for the treatment of CPP. Starting at a dose of 3.75 mg once every 28 days and increasing it with regard to findings in follow-ups would be a better approach.
ISSN:1687-8337
1687-8345
DOI:10.1155/2015/247386